AGEN Agenus
- 10.860
- +0.360+3.43%
- 10.830
- -0.030-0.28%
Agenus News
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)
HC Wainwright & Co. : The Agenus (AGEN.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $40.00.
HC Wainwright & Co. : The Agenus (AGEN.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $40.00.
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $40 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $40 price target.
Agenus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 230.85% HC Wainwright & Co. → $40 Reiterates Buy → Buy 03/18/2024 -58.64% B. Riley Securities $
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
Health care stocks rose Tuesday afternoon with the NYSE Health Care Index adding 0.8% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) fell 0.2%. In corpo
Agenus's Bot/bal: A Multifaceted Oncology Candidate Poised for Accelerated Approval and Market Expansion
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
Ligand Pharmaceuticals (LGND) and Agenus (AGEN) said Tuesday they have signed a royalty financing agreement to support the clinical development of Agenus' botensilimab and balstilimab, including a con
NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers
Agenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic Developments
Agenus (AGEN.US): The 2024 Q1 financial report achieved revenue of US$28.05 million, with a previous value of US$22.902 million, with an expected value of US$39.27 million; earnings per share was -US$3.04, previous value of -4.31 USD, and expected value o
Agenus (AGEN.US): The 2024 Q1 financial report achieved revenue of US$28.05 million, with a previous value of US$22.902 million, with an expected value of US$39.27 million; earnings per share was -US$3.04, previous value of -4.31 USD, and expected value of -2.83 USD.
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M
07:50 AM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M
Agenus Secures Strategic Finance Deal With Ligand
Outside CRC, Agenus Expects To Release Updated Phase 1 And 2 Data In Melanoma, Lung Cancer, Sarcoma And Pancreatic Cancer Later This Year.
Outside CRC, Agenus Expects To Release Updated Phase 1 And 2 Data In Melanoma, Lung Cancer, Sarcoma And Pancreatic Cancer Later This Year.
Agenus Q1 2024 GAAP EPS $(3.04) Beats $(3.14) Estimate, Sales $28.005M Miss $39.268M Estimate
Agenus (NASDAQ:AGEN) reported quarterly losses of $(3.04) per share which beat the analyst consensus estimate of $(3.14) by 3.18 percent. The company reported quarterly sales of $28.005 million which
Agenus 1Q Loss $63.5M >AGEN
Agenus 1Q Loss $63.5M >AGEN
Agenus 1Q Loss/Shr $3.04 >AGEN
Agenus 1Q Loss/Shr $3.04 >AGEN
Press Release: Agenus Reports First Quarter 2024 Results
Agenus Reports First Quarter 2024 Results $100M royalty financing agreement with Ligand announced, bringing in capital via non-equity means to support critical botensilimab/balstilimab (BOT/BAL) deve
Agenus Ended 1Q With a Cash and Cash Equivalent Balance of $52.9M >AGEN
Agenus Ended 1Q With a Cash and Cash Equivalent Balance of $52.9M >AGEN
Analysis
Price Target
No Data
